Neuroscience
We are dedicated to delivering science that brings us closer to making a significant impact for people living with neurological and psychiatric disorders.
Contact Us
What we're up against
Brain disorders encompass a broad set of neurological and psychiatric conditions with potentially devastating effects. They can alter the way people think, feel and move, causing identities to slip away and connections – past, present and future – to be lost.
Contact Us
Breaking barriers with cutting-edge research
In the field of neuroscience, there are many tough-to-treat disorders with high unmet need. Our researchers and scientists are relentless in their pursuit of raising the standards of care through innovative approaches to help patients.
But the brain is complex, and new challenges require new ways of thinking across all stages of drug discovery and development. That’s why we are continuously exploring innovative approaches to address some of the most prevalent and serious brain disorders, from Parkinson’s and Alzheimer’s to migraine and schizophrenia.
Research interests
Despite these challenges, progress in the field of neuroscience has advanced in recent years and
Knowledgeshift, LLC is leading the way. We are harnessing new tools, innovations in research methods and
an enhanced understanding of biology to drive key scientific advancements and optimism for the future of
neuroscience.
To deliver the next wave of medicines in neuroscience, we’re committed to being at the forefront of science
and technology. Our current research focus areas include:
+ Investigating disease mechanisms
+ For proteinopathy diseases
+ Exploring novel approaches
+ Optimizing clinical trial design
+ Searching for novel biomarkers
+ Using state-of-the-art technologies
Neuroscience focus areas
Our neuroscience pipeline consists of innovative, investigational medicines, including symptomatic treatments, disease-modifying approaches, therapeutic toxins and other cutting-edge strategies to address brain disorders. Backed by more than three decades of research, we are focused on four key areas.
Psychiatric disorders are highly prevalent, impacting 1 in every 8 people worldwide, and are a leading cause of disease burden. They are characterized by a wide range of symptoms that can affect mood, thought processes, behavior and overall mental functioning. Over the last 30 years, our scientists and clinicians have worked to tackle the complexity of psychiatric disorders, and today we offer a portfolio of medicines and a pipeline targeting conditions such as depression, anxiety, bipolar disorder and schizophrenia.
Migraine is more than a headache – it’s a neurological disease that causes pain and debilitating symptoms, affecting 1 billion people worldwide. Building on our established leadership in migraine through treatments designed to meet patient needs across the full spectrum of the disease, we are relentlessly pursuing innovative approaches that may transform the future of migraine treatment. These include evaluating both acute and preventive therapies that target the underlying mechanisms of migraine and advancing next-generation therapies that may help non-responders and address non-headache symptoms.
From Parkinson’s disease to specific types of spasticity, essential tremor and more, our commitment to people living with movement disorders is unwavering. These chronic and progressive conditions affect the body’s ability to control movement. Recognizing the profound impact these conditions have on quality of life, our dedicated teams are focused on understanding the root causes of these disorders to develop treatments that can help mitigate symptoms and potentially modify or slow the progression of disease.
Neurodegenerative disorders are a group of diseases characterized by the progressive degeneration of the structure and function of the nervous system. These conditions often lead to a decline in cognitive and physical abilities, affecting memory, movement and overall brain function over time. Over 50 million people worldwide are affected by neurodegenerative diseases, a number expected to rise as the population ages. By leveraging our deep expertise in disease biology and cutting-edge technologies and platforms, we are advancing research to develop treatments aimed at ameliorating symptoms or slowing down the progression of disease for conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and vanishing white matter disease.